The ongoing home for tirzepatide research news on this forum — peer-reviewed studies, trial updates, regulatory developments, conference presentations, label changes, and reliable scientific news.
Where things currently stand
- Mounjaro — FDA-approved for type 2 diabetes (May 2022).
- Zepbound — FDA-approved for chronic weight management (November 2023) and for moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024) — the first and only FDA-approved medicine for that indication.
- SURMOUNT-1 (NEJM, 2022) — pivotal obesity trial; 15 mg produced average weight loss of about 22.5% at 72 weeks.
- SURMOUNT-OSA — sleep apnea trial supporting the Zepbound OSA approval; reduced breathing disruptions by 25–29 events/hour vs. 5–6 with placebo.
- SURPASS-CVOT (NEJM, published December 2025) — tirzepatide was noninferior to dulaglutide on major cardiovascular outcomes in type 2 diabetes with atherosclerotic cardiovascular disease, with an approximately 8% relative reduction in three-point MACE and 16% reduction in all-cause mortality vs. dulaglutide.
What belongs in this thread
- New peer-reviewed publications
- Conference presentations
- Regulatory developments and label changes
- Official Eli Lilly announcements
- Reliable scientific news coverage
Please link the primary source (the journal article, the trial registry page, or Lilly’s own newsroom) when you post an update, rather than a secondhand summary.
Educational discussion of public research and regulatory disclosures — not medical guidance.
